Introduction {#Sec1}
============

The prevention of diabetes and control of its micro- and macrovascular complications has become one of the main public health challenges for the 21^st^ century, with the aim of attaining a significant reduction in the huge premature morbidity and mortality it causes, with a parallel reduction in health care costs (Shaw et al. [@CR33]). To this purpose, in addition to the implementation of strategies for diabetes prevention through lifestyle modification, a more aggressive control of the most important risk factors is urgently needed (American Diabetes Association [@CR1]). In fact, despite strong evidence that pharmacological interventions play an important role in preventing complications in individuals with diabetes, the mere dissemination of evidence-based guidelines often fails to deeply influence clinical practice.

The considerable pressure on health care systems to provide high-quality care while controlling costs has led several public and private health care organizations to promote initiatives to measure and improve the quality of care for patients with diabetes (Peters et al. [@CR22]; TRIAD Study Group [@CR37]; Ilag et al. [@CR18]; Saaddine et al. [@CR30][@CR31]). Quality measures identified include process and intermediate outcome indicators, selected under the assumption that they are linked to downstream health outcomes. These measures have been widely utilized to monitor quality of care and promote continuous quality improvement initiatives (Saaddine et al. [@CR30][@CR31]).

In Italy, the Associazione Medici Diabetologi (AMD) has implemented a continuous improvement effort involving over 300 diabetes clinics throughout the Country (Rossi et al. [@CR28]). To this purpose, AMD identified a set of quality indicators, including process and intermediate outcome measures. All indicators are compared with reference values, or "gold standard", established by identifying the best performers. By fixing as reference the results obtained by the best performers, specialists can easily realize the real margin of improvement made possible by simply increasing the level of attention to disease monitoring and treatment. The AMD Annals initiative allows a thorough description of the quality of care delivered every year by specialist structures to over 500.000 patients (Arcangeli et al. [@CR5]). In additional to cumulative analyses, AMD Annals also provide sub-analyses at the regional level, to facilitate the local use of the data for quality improvement initiatives. The initiative has already proven to be effective in improving several quality of care indicators (Nicolucci et al. [@CR21]).

Nevertheless, more structured benchmarking activities, involving discussion with clinicians, detection of obstacles at the local level, and identification of possible solutions are likely to produce further improvements in diabetes care. To this respect, a preliminary experience carried out in Sicily by a network of diabetes clinics documented a tangible improvement in the quality of diabetes care over 5 years (Club Diabete Sicili@ [@CR8]).

In recent years, there has been an increasing recognition of patient-centered care as the best model to ensure a care respectful of, and responsive to patient preferences, needs, and values ([@CR14]). The focus on patients' perspective has thus become particularly relevant. Despite the consensus that patient-centered care is an essential component of good diabetes care, most diabetes performance measures are solely based on clinical measures, and do not include psychosocial items. The need to include psychosocial aspects in the quality model of diabetes care has been clearly emphasized by the international Diabetes Attitudes, Wishes, and Needs (DAWN) Program. The DAWN Study has clearly shown that people with diabetes across 13 countries have major psychosocial issues that are not adequately addressed in the existing health care systems (Conference Report [@CR9]; International Diabetes Federation [@CR19]; Peyrot et al. [@CR24]; Skovlund and Peyrot [@CR34]; Wroe [@CR41]). Given these premises, the BENCH-D Study (Benchmarking Network for Clinical and Humanistic Outcomes in Diabetes) was designed to test a model of regional benchmarking activity aimed at improving not only the quality of diabetes care, but also patient-centered outcomes. The BENCH-D study is integral part of the DAWN-2 initiatives (Peyrot et al. [@CR26]) in Italy.

Methods {#Sec2}
=======

Objectives {#Sec3}
----------

Aims of the BENCH-D study are:To tests the feasibility of a regional model for quality improvement, based on a deep analysis of regional data coupled with a structured process for the identification of priority actions;To identify a core set of patient centered indicators to be adopted in conjunction with clinical indicators;To evaluate the impact of the benchmarking initiative in improving both clinical and patient-centered quality indicators.

Setting {#Sec4}
-------

The study involves 32 diabetes clinics in four different Italian regions (Piedmont, Marche, Lazio, and Sicily). Regions have been selected to reflect different levels of performance in terms of process and intermediate outcome measures, based on the information collected in the previous analyses of AMD Annals.

Clinical data collection {#Sec5}
------------------------

Following the methodology applied in the AMD Annals initiative (Rossi et al. [@CR28]; Arcangeli et al. [@CR5]; Nicolucci et al. [@CR21]), data are extracted from electronic databases of diabetes clinics using a specific software. Information on all patients seen in the clinic in the previous 12 months is collected, including age, gender, body mass index (BMI), smoking, diabetes duration, diabetes treatments, glycated hemoglobin (HbA1c), blood pressure and lipid profile values, microalbuminuria, serum creatinine, antihypertensive and lipid-lowering treatments, diabetes complications and other chronic conditions. A set of standard quality of care indicators is adopted, including process, intermediate and final outcomes, indicators of treatment intensity/appropriateness, and a global quality score.

Process measures are expressed as percentages of patients monitored at least once during the previous 12 months for the following parameters: HbA1c, blood pressure (BP), lipid profile, renal function, foot examination and eye examination.

Intermediate outcome measures include the proportion of patients with satisfactory values as well as the percentage of those with unacceptably high values. Satisfactory outcomes include HbA1c levels ≤7.0% (53 mmol/mol), BP values ≤130/80 mmHg, LDL cholesterol (LDL-C) levels \<100 mg/dl, and body mass index (BMI) \<27 Kg/m^2^. Unsatisfactory outcomes include HbA1c levels \>8.0% (64 mmol/mol), blood pressure values ≥140/90 mmHg, LDL levels ≥130 mg/dl, BMI ≥30 Kg/m^2^, presence of micro/macroalbuminuria, and GFR ≤60 ml/min.

Indicators of treatment intensity/appropriateness take into consideration the use of pharmacological treatments in relation to the achievement of the targets. This set includes: no insulin treatment in spite of HbA1c \> 9.0% (75 mmol/mol); HbA1c \>9.0% (75 mmol/mol) in spite of insulin treatment; no lipid-lowering agents in spite of LDL-c ≥130 mg/dl; LDL-c ≥130 mg/dl in spite of lipid-lowering treatment; no antihypertensive treatments in spite of BP ≥ 140/90 mmHg; BP ≥ 140/90 mmHg in spite of antihypertensive treatment; no ACE-inhibitors (ACE-I) and/or Angiotensin Receptor Blockers (ARBs) in spite of micro/macroalbuminuria.

A quality of care summary score (Q score) is also calculated. The Q score has been developed and validated in two previous studies (De Berardis et al. [@CR10]; Rossi et al. [@CR29]); it is based on a combination of process and intermediate outcome indicators relative to HbA1c, blood pressure, LDL-cholesterol and microalbuminuria. The score ranges between 0 and 40; the higher the score, the better the quality of care. The risk to develop a new cardiovascular event within 3 years was shown to be 80% higher in patients with a score \<15 and 20% higher in those with a score between 15 and 25, as compared to those with a score \>25 (De Berardis et al. [@CR10]; Rossi et al. [@CR29]).

Quality of life and patient satisfaction evaluation {#Sec6}
---------------------------------------------------

Information on quality of life and patient satisfaction is collected using ad hoc questionnaires. The questionnaire includes ten instruments, partially derived from the DAWN-2 study (Peyrot et al. [@CR26]).

Standardized instruments were incorporated into the questionnaires in original or shortened forms: SF-12 health survey, WHO Well-Being Index (WHO-5), Diabetes Empowerment Scale-Short Form (DES-SF), Problem Areas in Diabetes Scale 5 (PAID-5), Patient Assessment of Chronic Illness Care-Short Form (PACIC-SF), Health Care Climate Short Form (HCC-SF), Global Satisfaction with Diabetes Treatment (GSDT), Summary of Diabetes Self-Care Activities measure (SDSCA-6); Barriers to Medications (BM), Perceived Social Support (PSS).

All the questionnaires, with the exception of the already previously validated WHO-5 Well-Being Index (Bech et al. [@CR6]; Hajos et al. [@CR16]), have undergone a rigorous process of translation into the Italian language and psychometric validation specifically for the BENCH-D study. All the scale scores, with the exception of SDSCA-6, range between 0 and 100, with higher values indicating a higher level of the dimension measured. ***SF-12 Health Survey (SF-12)***: it is a widely used generic health status measure (Gandek et al. [@CR12]). It includes 12 items which can be aggregated into two summary measures: the Physical (PCS) and Mental (MCS) Component Summary scores. Both scores are normalized to a general population mean of 50 and a standard deviation of 10.***WHO-5 Well-Being Index (WHO-5)***: It assesses the psychological well-being, a core component of overall quality of life (Bech et al. [@CR6]; Hajos et al. [@CR16]). The use of WHO-5 is recommended in global and some national treatment guidelines for diabetes after its worldwide use in the DAWN initiative (Conference Report [@CR9]; International Diabetes Federation [@CR19]; Peyrot et al. [@CR25][@CR26]; Skovlund and Peyrot [@CR34]; Wroe [@CR41]). It is also a valid and reliable risk assessment measure for mild, moderate and severe depression and performs well in comparison to negative worded instruments such as the Brief Patient Health Questionnaire PHQ-9 or CES-D (Henkel et al. [@CR17]; de Wit et al. [@CR11]). It includes 5 items with responses on a six-point Likert scale. A score \< 50 indicates poor psychological well-being, while a score ≤28 indicates likely depression.***Diabetes Empowerment Scale -- Short Form (DES-SF)***: DES-SF provides a very brief but well validated instrument to assess the patient's confidence in taking an active role in own management of the condition (Anderson et al. [@CR2][@CR3]). An effective diabetes management requires an empowered diabetes patient, who is able to take personal charge of parts of the care plan, yet the extent to which educational and pedagogic efforts of the healthcare team are effective in empowering the patient is rarely measured. The instrument includes 8 items with responses on a five-point Likert scale.***Problem Areas in Diabetes -- Short form (PAID-5)***: PAID evaluates the emotional diabetes distress, i.e. patients specific worries and negative emotions related to their diabetes (McGuire et al. [@CR20]; Polonsky et al. [@CR27]; Welch et al. [@CR39]). It also complements the general well-being assessment with vital information about the patient's acceptance of and coping with diabetes-specific issues. The instrument has been applied in more than a hundred studies and in the DAWN MIND (Monitoring Individual Needs in People with Diabetes) program across 10 countries (McGuire et al. [@CR20]). The PAID-5 short-form has been validated in the multi-national DAWN MIND study and there is solid evidence that scores are clinically relevant. It includes 5 items with responses on a five-point Likert scale. A score ≥40 indicates high diabetes-related distress.***Patients Assessment of Chronic Illness Care -- Short form (PACIC-SF)***: In accordance with the evidence-based principles of patient-centered healthcare and the results of the DAWN initiative, the PACIC scale enables a concrete assessment of patient perceived access to support from the health care team according to a chronic care health delivery model (Glasgow et al. [@CR13]; Gugiu et al. [@CR15]). In this study we used the short-form version of the questionnaire, including 11 items with responses on a five-point Likert scale.***Health Care Climate Questionnaire -- Short form (HCC-SF)***: it evaluates the extent to which clinicians tend to favor the autonomy of the patient or, instead, tend to assume a paternalistic attitude towards the patient (Williams et al. [@CR40]). This instrument has been used in many studies on different diseases, including diabetes, and has proven to be able to predict an improvement in metabolic control (Schafer et al. [@CR32]). The study uses a short version of the questionnaire, consisting of 6 questions, with responses on 7-point Likert scale.***Global Satisfaction with Diabetes Treatment (GSDT)***: It assesses the perceived impact of medication on daily life and psychological well being, in addition to overall satisfaction for the pharmacological treatment (Brod et al. [@CR7]). It represents a very important element in determining the acceptance by the patient and adherence to therapy. The questionnaire was developed as part of the DAWN Study, and consists of 7 items with responses on 5-point Likert scales.**Summary of Diabetes Self-care Activities (SDSCA-6)**: it assesses health behaviours, notoriously difficult to evaluate reliably. The instrument has been shown to add relevant and useful information in the context of diabetes studies, even though data must be interpreted with caution as they are self-reported (Toobert et al. [@CR36]). The version of the SDSCA-6 includes 6 selected items with responses on 8-point Likert scales, indicating the number of days (from 0 to 7) in a week the patient adheres with the recommended behaviour. Each item is treated individually.***Barriers to Medications (BM)***: Compliance to medication is considered a key reason for suboptimal outcomes (Brod et al. [@CR7]; Snoek et al. [@CR35]; Anderson et al. [@CR4]). BM is a simple questionnaire focused on assessing what concrete barriers patients face in daily life to taking their medication as scheduled. It has been developed in the DAWN study (Conference Report [@CR9]; International Diabetes Federation [@CR19]; Peyrot et al. [@CR25][@CR26]; Skovlund and Peyrot [@CR34]; Wroe [@CR41]) and includes 10 items with responses on 6-point Likert scales.***Perceived social support (PSS)***: as demonstrated by the international DAWN study (Conference Report [@CR9]; International Diabetes Federation [@CR19]; Peyrot et al. [@CR25][@CR26]; Skovlund and Peyrot [@CR34]; Wroe [@CR41]), patient perception of access to support from multiple sources plays an important role. People with diabetes rely on support from the community, from family, peers and other sources on a daily basis, and understanding this level of support in addition to that provided by the healthcare system is essential, yet requires new questionnaires. The DAWN study included a very short questionnaire to assess satisfaction with support from various sources, which proved useful in determining the relative importance of these factors in patient's self-management (Peyrot and International DAWN Youth Survey Group [@CR23]). An optimized version of the questionnaire has been included in this study, including 5 items with responses on 5-point Likert scale.

Information on socio-demographic characteristics (age, gender, nationality, level of school education, working status, living status) are also collected through the questionnaire.

Questionnaires are anonymous, filled in by the patients on the occasion of a routine visit and sent to the coordinating center using sealed envelopes. The link between clinical and patient reported data is ensured by a univocal numerical code.

Patient recruitment {#Sec7}
-------------------

All patients seen in the participating centers during the previous 12 months are included in the evaluation of clinical indicators. Patient centered outcomes are evaluated in a sub-sample of patients, selected using random sampling lists, stratified by diabetes treatment (oral agents, insulin, insulin and oral agents). An additional sample of patients with newly diagnosed diabetes (diagnosis made in the last 12 months) has been also identified. Within each treatment group, the sample has been further stratified by gender.

Regional meetings {#Sec8}
-----------------

In each region, 5 meetings are scheduled, involving all the health care professionals participating in the initiative (diabetologists, nurses, dietitians).

In the first meeting, the aims and the operational aspects of the study were illustrated and discussed with participants.

The second meeting was focused on the discussion of the results relative to clinical indicators produced by the AMD Annals at the national and regional level. The "best performers" approach was used to compare the overall results obtained at the regional level with those obtained in those centers reaching the highest rates of performance for process and outcome measures. The session was organized according to a standardized structure. After the illustration of the results, each participant was asked to identify the three main problems emerging from the data. All the problems identified were then assigned by the participants a score from 0 to 10 for their relevance and a score from 0 to 10 for the concrete possibility to act on the problem. Problems were then ranked, and the first three were selected. Following the same procedure, three major obstacles causing the problems were identified and possible solutions proposed. The process led to the definition of a regional mandate, to be implemented in the following 12 months. The mandate did not require a radical change in the usual clinical practice, but rather an optimization of the work already done and a more appropriate use of the available resources.

The third meeting was focused on patient centered outcomes. Following the same methodology of the previous meeting, results of the quality of life and satisfaction survey were discussed, problems/barriers were identified, and possible solutions/actions proposed.

Eighteen months after the third meeting, clinical data will be extracted again, allowing a first evaluation of the impact of the initiative on clinical indicators. The impact of benchmarking activities on patient centered outcomes will be evaluated following a second survey conducted with the same patients participating in the first one. The results will be discussed on the occasion of the fourth meeting. Improvements registered and problematic areas where no improvements in performance will be documented will represent the core for discussion. Elements that have facilitated or represented an obstacle to improvement will be analyzed in detail, and actions to improve quality of care will be identified.

A final data collection on clinical indicators will be performed 12 months after the second clinical data extraction, and results will be discussed in the fifth meeting, which will represent the occasion for the assessment of the overall outcomes of the initiative. The results of this final assessment will be useful to identify the strengths and limitations of the approach adopted, and will help in better refining the overall approach before its extension to other regions.

The study design is reported in Table [1](#Tab1){ref-type="table"}.Table 1**Study design**TimePeriodRegional meetingActivityT-1October - November 2010First meetingPresentation of the protocolT0November 2010 - July 2011Administration of the first questionnaire to a random sample of patients. First clinical data extraction.T2September - October 2011Second + third meetingDiscussion of clinical and patient-centered indicators and definition of the regional mandate.T3March 2012Activation of regional mandate in the centers.T4March - July 2013Patient recall and administration of the second questionnaire. Second clinical data extraction.T5September - November 2013Fourth meetingIntermediate evaluation of the impact of benchmarking on clinical indicators. Final evaluation of the impact of benchmarking on patient-centered indicators.T6July 2014Third clinical data extraction.T7September - November 2014Fifth meetingFinal evaluation of the impact of benchmarking on clinical indicators.

Statistical analysis {#Sec9}
--------------------

Except for the SF-12 and the WHO-5, largely utilized in the Italian population, all the other quality of life scales have been translated, cross-culturally adapted and validated in Italian specifically for the BENCH-D study. The questionnaire was validated using a multitrait multi-item method ([@CR38]). This method is used to determine whether each item in a scale is substantially related (r ≥0.40) to the total score computed from the other items in that scale (item convergent validity criterion). Internal-consistency reliability was estimated by the Cronbach's alpha coefficient, with a minimum value of 0.70 considered as acceptable. Furthermore, the percentages of respondents achieving either the highest score (ceiling) and lowest score (floor) were calculated.

Patient characteristics and clinical indicators are described as mean and standard deviation or frequencies.

Scale scores are summarized as mean and standard deviation. All the data have been centrally analyzed anonymously.

Ethics considerations {#Sec10}
---------------------

The study protocol was approved by local ethics committees of participating centers. A written informed consent was obtained by all patients before the administration of the questionnaires.

The protocol was approved by the institutional review board of the Mario Negri Sud Foundation and by the scientific committee of the Associazione Medici Diabetologi.

Results {#Sec11}
=======

Recruitment {#Sec12}
-----------

Overall, 32 centers extracted by the electronic clinical record system information on 78,854 patients with type 2 diabetes for benchmarking activities based on clinical indicators, while 26 centers enrolled 2,390 patients for the validation and evaluation of patient centered outcomes. Socio-demographic and clinical characteristics of the patients who filled in the questionnaire are summarized in Table [2](#Tab2){ref-type="table"}.Table 2**Socio-demographic and clinical characteristics of patients recruited in the BENCH-D study*Variable**Mean ± std or %*N**2,390**Socio-demographic characteristics**% Males59.7%Mean age (years)65.0 ± 10.2School education (%)Primary school39.2Middle school28.8High school25.4University6.6Working status (%)Employed23.5Housewife14.4Retired59.7Unemployed/student2.4Marital status (%)Not married6.8Married77.9Separated/divorced4.4Widower10.9Living status (%)Alone11.9Spouse/sons82.8Other5.2Smokers (%)16.5**Clinical characteristics**Diabetes duration (yrs)14.0 ± 15.3HbA1c (%)7.7 ± 1.5HbA1c (mmol/mol)61 ± 16.4BMI (Kg/m^2^)30.2 ± 6.0Total cholesterol (mg/dl)177.7 ± 39.9HDL cholesterol (mg/dl)49.5 ± 14.6LDL cholesterol (mg/dl)100.9 ± 32.7Triglycerides (mg/dl)142.4 ± 112.4Systolic blood pressure135.3 ± 16.2Diastolic blood pressure78.3 ± 9.1Diabetes treatment (%)Oral agents49.5Oral agents + insulin25.8Insulin24.7Lipid-lowering agents (%)47.1Antihypertensive treatment (%)67.7Diabetes complications066.6125.0≥28.4

Validation of the questionnaires {#Sec13}
--------------------------------

The validation process was performed using all the questionnaires filled in by 2,390 patients enrolled. All the questionnaires showed excellent psychometric characteristics; for all scales, the Cronbach's alpha coefficient largely exceeded the minimum accepted value of 0.70 (Table [3](#Tab3){ref-type="table"}). On the same line, item-scale correlation was extremely satisfactory for all the scales. Percentages at ceiling and floor were equal to 0% for DES-SF, HCC-SF, PACIC-SF, GSDT, PSS, and BM and in an acceptable range for PAID-5 (10.2% at floor and 0% at ceiling).Table 3**Quality of life and patient satisfaction questionnaires used and validated in the BENCH-D study**QuestionnaireAbbreviationDomainNo. of itemsScoringCronbach's alphaItem-scale correlation (Min-Max)SF-12 Health Survey physical componentSF-12 PCSPhysical functioning60-100\--WHO-5 Well-Being IndexWHO-5Psychological well-being50-100\--Diabetes Empowerment Scale-Short FormDES-SFDiabetes Psychosocial Self-Efficacy80-1000.930.916-0.933Problem Areas in Diabetes 5PAID-5Diabetes distress5100-00.930.918-0.923Health Care Climate Questionnaire-Short FormHCC-SFPatient centered communication60-1000.930.909-0.927Patients Assessment of Chronic Illness Care-Short FormPACIC-SFQuality of chronic illness care and patient support110-1000.850.833-0.849Global Satisfaction for Diabetes TreatmentGSDTSatisfaction with treatment regimen70-1000.800.748-0.787Diabetes Self-care ActivitiesSDSCA-6Self-care activities60-7\--Barriers to MedicationsBMBarriers to medication100-1000.770.736-0.753Perceived social supportPSSPatient perceived support50-1000.810.748-0.830

Regional meetings {#Sec14}
-----------------

Meetings for the structured discussion of clinical and humanistic indicators have been held between September and October 2011. The approach adopted led to the identification of different priorities for intervention in the four regions, reflecting different organizational characteristics and specific needs.

The operational protocol has been officially launched in March 2012. The biggest challenge identified in all regions was to test innovative ways of communication with the patient, and to deal with his/her psychosocial needs. Table [4](#Tab4){ref-type="table"} shows as an example the problems and solutions proposed in one of the regions.Table 4**Examples of actions identified in the regional mandate**Problem areaActionQuality indicator to measure impact of benchmarkingMany patients with microalbuminuria are not treated with ACE-inhibitors and/or ARBsUse of an ad hoc query on the electronic clinical record to identify these patientsReduction in the percentage of patients with microalbuminuria not treated with ACE-inhibitors and/or ARBsMany patients with LDL-cholesterol ≥130 mg/dl are not treated with lipid-lowering agentsUse of an ad hoc query on the electronic clinical record to identify these patientsReduction in the percentage of patients with LDL-C ≥130 mg/dl not treated with lipid-lowering agentsPoor proactive involvement of patients in the process of careIdentification of a model of "therapeutic contract", with discussion and agreement on therapeutic goals and appointments for regular monitoring of diabetes complicationsIncrease in the percentage of patients reaching HbA1c, blood pressure and LDL-cholesterol targets. Increase in percentage patients monitored for nephropathy, retinopathy and diabetic footPoor attention to patient with low levels of psychological well-beingUse of WHO-5 to identify patients with score \<28; referral for specific counseling, identification of barriers and solutionsIncrease in mean values of WHO-5 and DES-SF scores and decrease in mean values of PAID-5

Discussion {#Sec15}
==========

The BENCH-D study allows the field testing of benchmarking activities based on a structured discussion of quality indicators, selection of priorities, and identification pertinent actions. Furthermore, the study includes for the first time in a benchmarking initiative a set of validated patient centered indicators and will document whether it is possible to improve not only clinical indicators, but also patient well-being and satisfaction with the care received. If successful, the initiative could be extended to other Italian regions, as well as to other health care systems. As a whole, this project can make an important contribution in promoting patient-centered care and improving the quality of diabetes care.
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